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Conclusion: The dummy-run showed that the most significant 
deviations were obtained when ROs did not precisely apply 
the CG. Such systematic deviations in the contouring could 
have a dosimetric impact both for target coverage and OAR 
sparing, especially for particle therapy. The ROs were 
provided with the developed graphical tool in order to easily 
identify their deviations and take corrective actions. The 
graphical tool could also be useful for the optimization of the 
contouring strategies within individual Institutes. 
This work was partially funded by Associazione Italiana per la 
Ricerca sul Cancro AIRC (grant N-14300) 
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Purpose or Objective: To evaluate the role of adjuvant 
androgen deprivation therapy (ADT) in combination with 
postoperative radiotherapy (PORT) on biochemical-relapse-
free-survival (b-NED) and metastatic-progression-free-survival 
(mts-NED) in high risk prostate cancer patients (pts). 
 
Material and Methods: Between 2004 and 2012 370 high risk 
prostate cancer pts received PORT : 120 pts had stage pT3a 
pN0, 150 pts pT3b pN0 , 100 pts pT2c/pT3 R1 and post 
surgical PSA > 0.2 ng/ml detected in 50 pts. Mean age was 72 
years (55-78 yrs). PORT on pelvis and surgical bed was 
delivered in 150 pts while 220 pts were treated on surgical 
bed . Dose to pelvis was 45-50 Gy, while dose on surgical bed 
was 66- 72 Gy. ADT was administerd in 250 pts and consisted 
of LH-RH analog in monotherapy (70 pts), BAT (60 pts) and 
bicalutamide 150 mg (120 pts). Timing of ADT ranged six 
months to 3 years. ADT was administered during and after 
PORT with a median of 35 months. Kaplan-Mayer b-Ned and 
mts-Ned survivals , X-square (p< 0.05) and paired t-test for 
univariate and multivariate analyses (p< 0.001) were 
calculated.  
 
Results: Three – hundred were evaluable at 64 months with a 
median of 5 years. Two groups were identified: ADT (210 pts) 
and no ADT (90 pts). One-hundred and twenty pts (120) 
relapsed: 40 pts in the no ADT group (5 with a biochemical 
relapse and 35 pts with a metastatic relapse) and 70 pts in 
the ADT group (20 pts with a biochemical relapse and 50 pts 
with a metastatic). The 5- year biochemical relapse free 
survival was 80% for ADT group and 78% for no ADT group (p = 
0.34); the 5-year metastatatic progression free survival for 
ADT group was 82 % vs 65% (p< 0.05)for no ADT group. In the 
ADT group, radiotherapy dose <70 Gy and PSA >0.2 ng/ml 
were indipendent factors related to high risk of biochemical-
relapse while metastatic-relapse-free-survival was influenced 
by primary component 5 of the Gleason Score (GS) , no use of 
LH-RH analog and time of ADT<2aa . In the no ADT group, PSA 
> 0.2 ng/ml, radiotherapy dose <70 Gy and R1 disease, were 
factors influencing the biochemical relapse, while 
metastastic relapse was influenced by a value of 5 in the 
Gleason Score. 
 
Conclusion: The role of ADT in adjuvant setting prostate 
cancer is still unclear; our results suggest a benefit of ADT in 
metastatic-progression-free-survival, especially in case of 
primary component 5 in the GS , post-operative PSA >0, 
BAT<2 years. 
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Purpose or Objective: This study reports long-term patient 
reported urinary function, toxicity and related quality of life 
(QoL) after external beam radiotherapy for localized prostate 
cancer. 
 
Material and Methods: 574 men underwent definitive 3D 
conformal radiotherapy to 74Gy ± androgen deprivation 
therapy between 2000 and 2009 with a median follow-up of 
42 months. Patients were evaluated at baseline and post 
treatment using the International Prostate Symptom Score 
(IPSS) and RTOG CTC. 
 
Results: For patients with mild (48%), moderate (40%) and 
severe (12%) baseline total IPSS, median IPSS at baseline was 
3,12, and 24. Median IPSS was 4, 9, and 12 at 6 months and 3, 
9 and 14 at 48 months respectively. Late grade 2 
genitourinary toxicity incidence was 7%, 20% and 33% and late 
grade 3 genitourinary toxicity was 1%, 2% and 1% 
respectively. At 48 months, 80%, 49% and 16% of patient with 
baseline mild, moderate and severe IPSS respectively 
demonstrated stable IPSS, 5%, 39% and 72% reported 
improving IPSS ≥5, and 14%, 12% and 6% had a worsening IPSS 
≥5. 82% of patients with mild baseline IPSS had mild IPSS 
scores. 95% of patients with moderate baseline IPSS had mild 
or moderate IPSS scores, with 43% improving to mild IPSS 
scores. 75% of patients with severe baseline IPSS scores had 
improved to mild (28%) or moderate (47%) IPSS scores. 68% of 
the cohort reported good baseline urinary QoL (score 0-2), 
with 89% of these patients maintaining good urinary QoL at 48 
months. 71% of patients with poor baseline urinary QoL (score 
3-6) had improved to good urinary QoL. 
 
 
 
Conclusion: The majority of men undergoing definitive 
radiotherapy for prostate cancer report stable or improving 
late urinary symptom burden and urinary quality of life, even 
with severe urinary symptoms or poor urinary quality of life 
at baseline. 
 
 
 
 
